Dow Down0.25% Nasdaq Down0.14%

Myriad Genetics Inc. (MYGN)

-NasdaqGS
38.87 Up 0.98(2.59%) Sep 29, 4:00PM EDT
|After Hours : 39.32 Up 0.45 (1.16%) Sep 29, 4:28PM EDT
ProfileGet Profile for:
Myriad Genetics Inc.
320 Wakara Way
Salt Lake City, UT 84108
United States - Map
Phone: 801-584-3600
Fax: 801-584-3640
Website: http://www.myriad.com

Details 
Index Membership:N/A
Sector:Services
Industry:Research Services
Full Time Employees:1,649

Business Summary 

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests in the United States and internationally. The company operates through three segments: Research, Molecular Diagnostics, and Pharmaceutical and Clinical Services. The company’s molecular diagnostic tests are designed to analyze genes; diagnose diseases, expression levels, and proteins to assess an individual’s risk for developing disease later in life; determine a patient’s likelihood of responding to a particular drug; and assess a patient’s risk of disease progression and disease recurrence. It offers various molecular diagnostic tests, including BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; EndoPredict medicine test for breast cancer; and MELARIS predictive medicine test for hereditary melanoma. The company also provides myPath Melanoma diagnostic medicine test for melanoma; myPlan lung cancer, a prognostic medicine test for lung cancer; myRisk Hereditary Cancer, a predictive medicine test for hereditary cancer; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and Vectra DA, a personalized medicine test for rheumatoid arthritis. In addition, it offers biomarker discovery, and pharmaceutical and clinical services to pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Key Statistics


Company Websites 
Home Page
Investor Relations
Employment
Search Yahoo! for:
More on Myriad Genetics Inc.

Corporate Governance 
Myriad Genetics Inc.’s ISS Governance QuickScore as of Sep 1, 2014 is 9. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 7; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. Peter D. Meldrum Ph.D., 67
Chief Exec. Officer, Pres and Director
2.21M5.77M
Dr. Walter A. Gilbert Ph.D., 82
Founding Scientist, Vice Chairman and Member of Compensation Committee
67.00KN/A
Mr. James S. Evans , 51
Chief Financial Officer, Principal Accounting Officer and Treasurer
796.00K2.33M
Dr. Jerry S. Lanchbury Ph.D., 55
Chief Scientific Officer
713.00K2.16M
Mr. Richard M. Marsh Esq., 56
Exec. VP, Gen. Counsel and Sec.
727.00K2.83M
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders